Shortened and intensified MJMA: An effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs

Bone Marrow Transplantation

Volumn 44, Issue 1, 2009, Pages 19-25

  Gobbi, P G ^a   Valentino, F ^a   Lambelet, P ^b   Perfetti, V ^a   Bergamaschi, G ^a   Girino, M ^a   Corazza, G R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Ospedale Unico della Versilia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; INTERFERON; LOMUSTINE; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; RITUXIMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; BODY WEIGHT; CANCER RELAPSE; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HODGKIN DISEASE; HUMAN; LYMPHOCYTOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SALVAGE THERAPY; STEM CELL MOBILIZATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MITOXANTRONE; RECURRENCE; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS;

EID: 67651097580     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.421     Document Type: Article

References (31)

1. Macdonald DA, Connors JM. New strategies for the treatment of early stages of Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007; 21: 871-880.
2. Diehl V, Engert A, Re D. New strategies for the treatment of advanced Hodgkin's disease. Hematol Oncol Clin North Am 2007; 21: 897-914.
3. Canellos GP. Relapsed and refractory Hodgkin's lymphoma: New avenues? Hematol Oncol Clin North Am 2007; 21: 929-941.
4. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
6. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemosensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
7. Shipp MA, Harrington D, Anderson JR, Armitage JO, Bonadonna G, Brittinger JG et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
8. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
9. Sica S, Di Mario A, Salutari P, Etuk B, Jovino MS, Pierelli L et al Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and GCSF in patients with resistant lymphoma. Am J Hematol 1994; 46: 18-23.
10. Ortu La Barbera EO, Chiusolo P, Laurenti L, Menichella G, Di Febo AL et al. MiCMA: An alternative treatment for refractory or recurrent Hodgkin's disease. Ann Oncol 2000; 11: 867-871.
11. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
12. Dixon DO, Mc Laughlin P, Hagemeister FB, Emil JF, Fuller LM, Cabanillas FF et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 1987; 5: 1670-1673.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al Toxicity and response criteria of the Estern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 569-573.
15. La Sala A, Dell'Olio M, Di Renzo N. MIPE vs. MJMA nella terapia di salvataggio del LNH aggressivo: Studio prospettico, randomizzato del GISL. Riassunti del 35° Cong. Soc. Ital. Ematol. (Pavia, 10-13/9/1995) Edimes, Pavia, 1995; 297p.
16. Sorà F, Piccirillo N, Chiusolo P, Laurenti L, Marra R, Bartolozzi F et al. Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation. Cancer 2006; 106: 859-866.
17. Oyan B, Koc Y, Ozdemir E, Kars A, Turken A, Tekuzman G et al. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease and non-Hodgkin lymphomas: A salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 688-697.
18. Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ et al. Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Ai Zheng 2005; 24: 465-469.
19. Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A et al. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies. Oncol Rep 2005; 14: 933-940.
20. Müller-Beissenhirtz H, Kasper C, Nückel H, Dührsen U. Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, result of a phase II single center study. Ann Hematol 2005; 84: 796-801.
21. Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006; 24: 593-600.
22. Atta J, Chow KU, Weidmann E, Mitrou PS, Hoelzer D, Martin H. Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2007; 48: 349-356.
23. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient fractionated ifosfamide, carboplatin, and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's lymphoma. Ann Oncol 2006; 17(Suppl 4): 25-30.
24. Simpson L, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Ristow KM et al. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cisplatinum, cytosine arabinoside, and dexamethasone. Leuk Lymphoma 2007; 48: 1332-1337.
25. Park SH, Kim S, Ko OB, Koo JE, Lee D, Jeong YP et al. ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: A single center experience. Korean J Intern Med 2006; 21: 159-164.
26. Di Renzo N, Brugiatelli M, Montanini A, Vigliotti ML, Cernetti G, Liberati AM et al. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractorry aggressive non-Hodgkin's lymphoma: Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. Leuk Lymphoma 2006; 47: 473-479.
27. Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing slvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study. Ann Oncol 2006; 17(Suppl 4): 18-24.
28. Lòpez A, Gutierrez A, Palacios A, Blancas I, Navarrete M, Morey M et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: A phase II study. Eur J Haematol 2007; 80: 127-132.
29. Sirohi B, Cunningham D, Norman A, Last K, Chau I, Horwich A et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without rituximab in relapsed and refractory patients with diffuse large B-cell lymphoma. Hematology 2007; 12: 149-153.
30. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M et al. Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007; 92: 35-41.
31. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F et al Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008; 112: 831-836.